YK Hamied thinking about his succession plans As the clock struck 9 Yusuf Hamied leaned back in his chair, took off his glasses and clinched his eyes. It had been a long day for the 79 year old veteran, not that he wasn’t used to it. He had spent countless hours in that office since 1960 chalking out plans and strategies that elevated Cipla to the pinnacle of Indian pharmaceutical industry. Indomitable and indefatigable as he may be, he had held the helm for ages now, and it was time for his nephew Kamil to steer the ship forward. But as it turned out Yusuf Hamied was staring at Kamil Hamied’s official resignation, who decided to quit Cipla after 7 years to pursue his personal career objectives. Yusuf Hamied had been mentoring Kamil and his …show more content…
The pharma companies in general are optimistic about the M and A. The growth of the pharmaceutical industry is expected to be driven by the diabetes, skincare and eye care segment. The leading pharmaceutical companies including Cipla is expected to be the part of the governments ‘Jan Aushadhi’ project with the aim of commercialising the project by procuring general drugs from them in bulk. The government plans to the Jan Aushadhi stores to 3000 by 2016. Company overview: Cipla Khwaja Abdul Hamied established Cipla in 1935 but it was only in 1937 that he was able to start the production of the drugs. Cipla is an acronym for the chemical, industrial and pharmaceutical laboratories. Today the production facilities of the companies are spread across locations in India like Goa, Patalganga, Kurkumbh, Mumbai, Vikhroli and Bangalore. Cipla, apart from having a strong presence in the Indian market, have a prospering export market and exports to more than 150 countries. Cipla has a huge product portfolio containing more than 200 brands of which some are leading in their categories. Apart from this, the company has excellent process RnD skill. The extensive distribution network makes Cipla, the biggest pharma company in
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals compounds for medical purpose. Pharmaceutical companies produce generic, brand medications and medical devices. The industry is subject to a complex regulatory environment regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs.
...ll help the company in selling generic drugs and provide affordable medications to its customer base.
“Filling the shoes of a remarkable, experienced, and thoughtful leader such as Mr West is a formidable task. However, I am really honored to have been given such a wonderful opportunity and excited about the challenges and opportunities that lie ahead,” said Mr. Leschly. This is a huge step forward in my career and I am looking forward to leading the company as we embark on this new journey. The company has a reputable history of leadership and success in the pharmaceutical industry and I hope to
PharmaCARE is one of the world 's most successful pharmaceutical companies that is enjoying a status as a nurturing, ethical and well-run business that manufactured high-quality healthcare products. Thus, saved millions of inhabits and enhanced the value of life for millions of people. The company provides free and discounted pharmaceuticals to low-income customers on the base of sponsors health care informative programs and scholarships. Two years before, after PharmaCARE 's research identified that one of its peak trading diabetes drugs (AD23) might slow the progression of Alzheimer 's infection. After identifying the weakness, its pharmacists began reformulating that pharmaceutical to maximize the effect. To avoid FDA inspection, PharmaCARE used US law to protect its intellectual property as it established a wholly-owned subsidiary, CompCARE that is set up beside its parent’s headquarters in a suburban agency park.
...s: each was licensed to a much larger firm because the originator firm lacked the capability to market the drug. the larger analysis of blockbuster drugs showed that this thread is common across blockbusters that originated with smaller firms. The largest firms appear to hold a significant advantage in commercialization—they are highly effective at extracting the value of innovative drugs . The study suggests some qualified reasons for skepticism that the end of the blockbuster era will bring a major upheaval in the industry. Large firms’ advantage in commercialization suggests that they may maintain their dominant position. Marketing of pharmaceuticals may move from broad-based to targeted approaches, but a company with a broad reach may still have an advantage in identifying markets for niche drugs and commercializing the drugs within those more narrow market
The Indian pharmaceutical industry enjoys certain advantages, which include low cost of innovation and capital expenditure, and strong domestic support in production, from raw material requirements to finished goods. The competitive structure of the pharmaceutical industry was being redefined due to the threat of new entrants, intense price competition, entry of large players, and new regulations and rules as well as a shift in focus. In addition, the partnerships between pharmaceutical and biotechnology companies were growing rapidly. The global pharmaceutical market is undergoing rapid transformation. There has been a dramatic shift towards emerging markets as western markets slow down.
...steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health in various dosage forms. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices, such as dry powder inhalers, single-dose capsule and multi-dose dry powder inhalers, breath-actuated metered dose inhalers, non-static spacers, baby and infant masks, and nasal sprays. Further, it provides consulting, commissioning, plant engineering, and technical know-how transfer and support services. Cipla has over 2000 products in 65 therapeutic categories available in over 40 dosage forms. Its key products include the following drugs - Escitalopram (anti-depressant), Lamivudine, Fluticasone propionate.
Pharmacy appeals to me because of its potential to ease people’s physical and emotional suffering. The simple act of listening and being empathetic to the concerns of other’s health and wellbeing has inspired me to learn more about the profession. Perseverance in college followed by the biotech industry has provided me with the necessary research skills to be successful. The ever-changing pharmacy field would allow me to continue my education, culminating in an exciting career.
Paragon Biosciences has been at the forefront of aiding the creation of new innovative pharmaceutical companies since the first day it was founded. The highly successful business strategy that Paragon Biosciences duplicates
Pfizer is the largest American pharmaceutical company and one of the largest pharmaceutical companies in the world. It competes with Merck and Glaxo, and markets such well-known medications as Celebrex and Viagra. However, the pharmaceutical industry as a whole has undergone changes in recent years with significant consolidation taking place and with increased scrutiny regarding the ways in which drugs are developed, tested and marketed. In addition, recent controversies have erupted regarding Merck's drug Vioxx, and Pfizer has been the target of unwanted publicity regarding its painkiller Celebrex. This research considers the strategic position of Pfizer, including its strengths and weaknesses as well as the opportunities and threats that it faces, its strategic priorities and the acquisition strategy that it might follow.
Teva Pharmaceuticals, the firs multinational pharmaceutical company of Israel had become a successful global giant in the industry of generic drugs. After experiencing a long period of success and growth in the generic drug industry against some big western pharmaceuticals the company had acquired many well known pharmaceutical companies and had achieved its goal of 1 billion dollar theory seemed to be in troubles in building a new strategy and vision to compete with the rapidly growing generic industry. They confronted two big issues as key hurdles in their way.
This relates strongly with my long term professional goals. In the long run, I really wish to help as many people as I can by advancing pharmacy. It is a dream to be able to go to a developing country or be part of an organization such as the World Health Organization and spread the knowledge of pharmacy and bring h...
The original case was about Chiron, a biotechnology company, in the United States. Chiron was acquired in 2006 by Novartis, a Swedish company formed by the merger of Ciba-Geigy and Sandoz Laborites. Since Chiron itself no longer exists, we have focused our case around Novartis as of 2013. Novartis specializes in diagnostic services, generic and name brand medications, ophthalmological tools, as well as a small segment in pet health. The business prides itself in producing the latest drugs, hiring the best talent, and being a global leader in the pharmaceutical industry. Over the years the company has survived by focusing on its internal development in addition to a series of mergers, acquisitions, and corporate restructurings. Being a pharmaceutical company, the entire population is impacted: patients, physicians, employees, hospitals, and investors are some of the most important stakeholders.
In reviewing the case of Fred Maiorino, a successful salesperson for Schering-Plough for over three decades, a lot of factors came into play in which were not favorable for both Fred, who as a result lost his job, and the management of Schering-Plough, in particular Jim Reed, the sales manager for the company.
The company shows a flat organization in which there are few layers of management but has broad span of control. According to the chart, the company develops a decentralized authority in the level of their management due to which they focus more on adapting to what customer wants based on decision making from the lower level managers who are more familiar in the local conditions. This type of authority allows them to understand customers such as patients’ needs in order to develop strategies to fulfill this requirement According to Figure 1, they primarily focus more on the health care system and invested in about $7.5 billion dollars in research and development to create a strong product portfolio. The culture of this organization demonstrates a formal organization in order to guide the lines of authority as well as the responsibility for the company. According to Johnson and Johnson Credo statement, their main focus is towards the responsibilities of the doctors, nurses, and patients as well as their employees. They also state their growing responsibilities toward the shareholders and to the communities in order to research and develop new innovations in towards civic improvement to the communities. This entails that they fully care for their customers and employees in which its shows in